acute confusional state delirium
Conditions
Interventions
All patients will receive a single dose of 3 mg haloperidol, 10 patients will
receive this by way of oral administration and 10 patients by way of
intravenous injection.
Sponsors
Kennemer Gasthuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: hip fracture surgery 65 years or over DRAS score 5 or over informed consent
Exclusion criteria
Exclusion criteria: haloperidol allergy QTc prolongation Parkinsons's disease Lewy body dementia use of anticoagulents liver failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nonlinear mixed effects model describing the population pharmacokinetics of haloperidol in the central and peripheral compartment after oral and intravenous injection. | — |
Secondary
| Measure | Time frame |
|---|---|
| Occurrence of adverse events and occurrence of postoperative delirium | — |
Countries
Netherlands
Outcome results
None listed